RE:RE:sigh What's clear (to me) on this news release is that they are pushing to collate whatever is needed to submit for BTD. I suspect that they have targeted having a particular amount of information (i.e., on a certain number of patients), which the FDA has probably told them they should (or need to) have for the submission... and once that target is reached... bada bing bada boom... they submit for the BTD.
And THAT (the actual submission for BTD) will be sufficient to pop the price quite nicely. Because we (i.e., the market) will not wait for the FDA's response to the submission (I think the FDA has 60 days to respond, if I'm remembering that right) And, given the warrants are due to expire in late August, I suspect that the push is on to get the sumission for BTD in well ahead of that. Which, all fits with the projection of BTD approval in 3rd quarter...
but, what do i know...